Articles

Fasenra, which has been approved since 2019 in the United States in a pre-filled, single-use auto-injector form that can be administered either in a doctor’s office or at home, is now approved in China for age 12 and up.

Severe Eosinophilic Asthma Maintenance Treatment Approved in China for Ages 12 and Up

Approximately 15% of all lung cancers diagnosed in the US are of the small-cell variety, and of those, 70% are considered extensive-stage.

GSK Gets FDA Breakthrough Therapy Designation for Small-Cell Lung Cancer Treatment

Genentech will have access to Sangamo’s capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines for certain neurodegenerative diseases.

Genentech Enters an Approximately $2 Billion Deal to License Sangamo Therapeutics Technologies for Developing Neurodegenerative Disease Therapeutics

NexoBrid, a topically administered biological product, is now authorized for use in all age groups in the United States, European Union, and Japan.

FDA Approves Pediatric Indication for Non-Surgical Severe Thermal Burn Treatment

Breyanzi demonstrated an overall high response rate in adults with relapsed or refractory follicular lymphoma in a Phase II study.

EMA Expands Indication for Bristol Myers Squibb Follicular Lymphoma Therapy

The agreement specifies that Nanoform will provide non-GMP nanomaterial to Takeda for in-vivo studies, the first results of which should be delivered by early 2025.

Nanoform and Takeda to Collaborate on Plasma-Derived Therapy Formulation

A Phase III study showed that 62% of patients given Livdelzi achieved the primary endpoint of composite biochemical response after 12 months, compared to 20% of participants taking placebo.

FDA Grants Accelerated Approval to Gilead Treatment for Primary Biliary Cholangitis

National Institutes of Health’s National Institute of Allergy and Infectious Diseases collaborated with the University of Sciences, Techniques and Technologies of Bamako, Mali to conduct the trials.

Experimental Malaria Vaccine Found to be Safe in Multiple Trials in Mali

Imfinzi may be used alone, or with chemotherapy in tandem with the other approved treatment, Lynparza.

Two AstraZeneca Treatments for Endometrial Cancer Approved in EU

Yorvipath is a prodrug of parathyroid hormone (PTH) (1-34), designed to be administered once daily to provide continuous exposure to released PTH.

News